![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Approves Eli Lilly’s New Insulin Lyumjev
FDA Approves Eli Lilly’s New Insulin Lyumjev
June 17, 2020
The FDA has approved Eli Lilly’s new rapid-acting insulin Lyumjev (insulin lispro-aabc injection) for increasing glycemic control in adults with type 1 and type 2 diabetes.
The approval was based on two phase 3 clinical trials in which Lyumjev demonstrated superior reduction in blood glucose spikes compared to Humalog at one hour and two hours after a meal.
Lyumjev is a novel formulation of insulin lispro developed to speed absorption of insulin into the bloodstream and reduce average blood sugar levels.
Upcoming Events
-
21Oct